ArticleBMC cancer2025
Relationships between growth rate and Ki-67 and immune indices in ground-glass nodule-featured lung adenocarcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Assessment of risk factors in persistent subsolid pulmonary nodules based on CT dynamic follow-up.BMC medical imaging · 2026Article
- Narrative review: the research advances of artificial intelligence in the prediction of pulmonary nodule growth.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study aimed to explore the correlation between the growth rate of resected ground glass nodule-featured lung adenocarcinomas (GGN-LUAD) and Ki-67, as well as various immune indexes, in patients with a follow-up period exceeding one year. MATERIALS AND
methodsSixty-seven tumors were divided into a growth group and a non-growth group. The volume doubling time (VDT) and mass doubling time (MDT) of the growth nodules were calculated. Immunohistochemical methods were used to detect the expression of Ki67, CD3, CD4, CD8, CD20, CD68, and CD163 in pulmonary nodules. The relationships between these immune markers and the growth of GGN-LUAD were explored. At VDT = 600 days, the growth nodules were divided into a fast-growth group and a slow-growth group.
resultsThe median VDT and MDT were 1059.3 and 947.9 days, respectively, for 49 growth GGN-LUAD. Compared with that in the non-growth group, the percentage of Ki67 positive cells in the growth group was significantly greater (p = 0.001). Among the 49 growth nodules, there was a significant correlation between CD3, Ki-67 and the VDT (p = 0.020; p = 0.003), and a significant negative correlation between Ki-67 and the MDT (p < 0.001). In the 32 pathologically proven growth invasive adenocarcinoma (IAC) subgroups, a strong positive association between CD3 expression and VDT was discovered (p = 0.029), and a significant negative correlation between Ki-67 and MDT (p = 0.014). The CD3 of the slow-growth group was substantially higher than that of the fast-growth group (p = 0.034).
conclusionThis study preliminarily explored the relationships among Ki-67 expression, the molecular immune characteristics of lung adenocarcinoma and its growth course. Higher Ki-67 expression is more likely associated with the growth of GGN-LUAD. In addition, higher CD3 expression is associated with the slow growth of GGN-LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.